The mission of the Pharmacogenomics Research Network (PGRN) is to catalyze and lead research in precision medicine for the discovery and translation of genomic variation influencing therapeutic and adverse drug effects.
CPIC’s goal is to address some of the barriers to implementation of pharmacogenetic tests into clinical practice.
Pharmacogene Variation Consortium
PharmVar serves as a central repository for pharmacogene variation to facilitate allele (haplotype) designation and the interpretation of pharmacogenetic test results to guide precision medicine.
A new PGRN, PGRN IV, established July 1, 2015, represents a continuation of these research activities, however in a new model. This new model invites participation of all investigators with an interest in pharmacogenomics research to be part of the new network.
Currently, the newly formed PGRN consists of three large center grant projects, two enabling resources for pharmacogenomics, a knowledgebase, PharmGKB, and a PGRN Hub, established to coordinate activities of the new PGRN in order to catalyze research in pharmacogenomics and precision medicine.
The Pharmacogenomics Research Network, PGRN I–III was funded from 2000 through 2015 by multiple Institutes and Centers of the NIH. The network catalyzed pharmacogenomics discoveries both nationally and internationally through the conduct of collaborative research focused on the discovery and translation of the genetic determinants of drug response, in order to enable safer and more effective drug therapies.